Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brilliance NT2: ALKS 2680 in Narcolepsy Type 2
NCT07502443Phase 3Recruiting
- Sponsor
- Alkermes
- Start
- Apr 2026
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of alixorexton in narcolepsy type 2 (NT2), sponsored by Alkermes. Started Apr 2026; status: recruiting.
02
Drugs
alixorexton
03
Conditions
narcolepsy type 2 (NT2)
Beyond the preview
Go deeper on NCT07502443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07502443.